Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Bevacizumab 4Zoledronic Acid 3Cisplatin 3Capecitabine 3spartalizumab 2anlotinib 2Radiotherapy 2Positron Emission Tomography Computed Tomography 2Metformin 2Letrozole 2Drug Therapy 2vosaroxin 1venetoclax 1tislelizumab 1pembrolizumab 1enzalutamide 1empagliflozin 1atezolizumab 1apatinib 1abiraterone 1XELOX 1Vacuum Curettage 1Tyrosine Kinase Inhibitors 1Tuberculin 1Sorafenib 1Sodium Chloride 1S 1 (combination) 1Radiotherapy, Intensity-Modulated 1Radiosurgery 1Prednisone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER_GOV × Poly(ADP-ribose) Polymerase Inhibitors × Clear all
NCT07472140 2026-03-16

PARP (Poly (ADP-ribose) Polymerase) Inhibitor With or Without Angiogenesis Inhibitor in Homologous Recombination Deficient Primary Ovarian Cancer, Fallopian-Tube Cancer, or Primary Peritoneal Cancer

N.N. Alexandrov National Cancer Centre

Phase 2/3 Recruiting
120 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡